Diferencia entre revisiones de «Cefepime»

Sin resumen de edición
(Remove disease-specific entries now covered by AntibioticDose (3 sections))
 
(No se muestran 4 ediciones intermedias de 2 usuarios)
Línea 10: Línea 10:
*1-2 g IV q12H (Max: 6 g/24h; dose, duration varies with infection type, severity)
*1-2 g IV q12H (Max: 6 g/24h; dose, duration varies with infection type, severity)


===Febrile Neutropenia===
*2g IV q8H
===[[UTI]], mild-moderate===
*0.5-1g IV/IM q12H x7-10 days (IM only for UTI due to E. coli)
===[[UTI]], severe===
*2g IV q12H x10 days


===Renal dosing===
===Renal dosing===
Línea 25: Línea 17:
===Hepatic Dosing===
===Hepatic Dosing===
*no adjustment
*no adjustment
===Indications by Disease===
{{#ask: [[Has DrugName::Cefepime]] [[Has Population::Adult]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Pediatric Dosing==
==Pediatric Dosing==
Línea 34: Línea 39:
*>2 mo: Dose: 50mg/kg IV/IM q12h; Max: 2 g/dose; Info: duration varies with infection type, severity; IM only for mild-mod. UTI due to E. coli
*>2 mo: Dose: 50mg/kg IV/IM q12h; Max: 2 g/dose; Info: duration varies with infection type, severity; IM only for mild-mod. UTI due to E. coli


===Febrile Neutropenia===
*>2 mo: Dose: 50mg/kg IV q8h; Max: 2 g/dose


===Respiratory Infections, cystic fibrosis patients===
*>2 mo: Dose: 50mg/kg IV q8h x2wk; Max: 2 g/dose


===Renal Dosing===
===Renal Dosing===
Línea 46: Línea 47:
===Hepatic Dosing===
===Hepatic Dosing===
*No Adjustment
*No Adjustment
===Indications by Disease===
{{#ask: [[Has DrugName::Cefepime]] [[Has Population::Pediatric]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Special Populations==
==Special Populations==
Línea 171: Línea 185:
| ||[[Acinetobacter sp.]]||I
| ||[[Acinetobacter sp.]]||I
|-
|-
| ||[[Pseudomonas aeruginosa]]||'''S'''
| ||[[Pseudomonas aeruginosa]]||'''[[Has Antipseudomonal::S]]'''
|-
|-
| ||[[Burkholderia cepacia]]||I
| ||[[Burkholderia cepacia]]||I

Revisión actual - 11:07 20 mar 2026

General

  • Type: 4th generation cephalosporins
  • Dosage Forms: infusion solution, powder for injection
  • Dosage Strengths: infusion solution: 1g/50mL, 2g/100mL; powder for injection: 1g, 2g
  • Routes of Administration: IV, IM
  • Common Trade Names: Maxipime

Adult Dosing

Bacterial Infections

  • 1-2 g IV q12H (Max: 6 g/24h; dose, duration varies with infection type, severity)


Renal dosing

  • Febrile Neutropenia: CrCl 30-60: 2 g q12H; CrCl 11-29: 2 g q24H; CrCL <11: 2gx1, then 1g q24H; HD: 1g q24H, give after dialysis; PD: 2g q48H
  • All other infections: CrCl 30-60: give q24h; CrCl 11-29: give usual dose x1, then 0.5-1 g q24h; CrCl <11: give usual dose x1, then 250-500mg q24h; HD: 1 g x1, then 500mg q24h, give after dialysis; PD: give usual dose q48h

Hepatic Dosing

  • no adjustment


Indications by Disease

DiseaseDoseContext
Acute cystitis2gm IV q8hrInpatient
Diabetic foot infection2g IV q12hrsInpatient DFI
Discitis2g IV three times dailyInpatient Therapy
Ludwig's angina2 g IV q12 hrsImmunocompromised
Neutropenic fever2g IV q8hrsInpatient monotherapy
Peritonitis2g IV once dailyAllergy/Prior exposure
Pneumonia (main)2g q8hICU, Risk of Pseudomonas
Pneumonia (main)2g q8hHAP, High Risk
Pneumonia (main)2g q8hVAP, High Risk
Pyelonephritis2gm IV q8hrAdult Inpatient

Pediatric Dosing

  • Mild to moderate infection: 50 mg/kg/dose every 12 hours; maximum dose: 2,000 mg/dose
  • Severe infection: 50 mg/kg/dose every 8 to 12 hours; maximum dose: 2,000 mg/dose

Bacterial Infections

  • >2 mo: Dose: 50mg/kg IV/IM q12h; Max: 2 g/dose; Info: duration varies with infection type, severity; IM only for mild-mod. UTI due to E. coli


Renal Dosing

  • Febrile Neutropenia, cystic fibrosis: CrCl 30-60: 50mg/kg q12h; CrCl 11-29: 50mg/kg q24h; CrCl <11: 50mg/kg x1, then 25mg/kg q24h; HD: 25mg/kg q24h, give after dialysis; PD: 50mg/kg q48h
  • all other infections: CrCl 30-60: 50mg/kg q24h; CrCl 11-29: 50mg/kg x1, then 25-50mg/kg q24h; CrCl <11: 50mg/kg x1, then 12.5-25mg/kg q24h; HD: 50mg/kg x1, then 25mg/kg q24h, give after dialysis; PD: 50mg/kg q48h

Hepatic Dosing

  • No Adjustment


Indications by Disease

DiseaseDoseContext
Cystic fibrosis>2 mo: Dose: 50mg/kg IV q8h x2wk; Max: 2 g/doseRespiratory Infections, cystic fibrosis patients
Ludwig's angina50mg/kg IV q8hrs (max 2g)Pediatric Immunocompromised
Neutropenic fever50mg/kg IV q8hrs (max 2g)Pediatric Inpatient
Pediatric fever of uncertain source30mg/kg/doseNeonatal 0-14 days with Ampicillin
Pneumonia (peds)50mg/kg/dose q8hrs IVHospitalized PICU severely ill

Special Populations

  • Pregnancy: B
  • Lactation: Probably safe
  • Renal Dosing
    • Adult: CrCl 30-60: give q24h; CrCl 11-29: give usual dose x1, then 0.5-1 g q24h; CrCl <11: give usual dose x1, then 250-500mg q24h; HD: 1 g x1, then 500mg q24h, give after dialysis; PD: give usual dose q48h
    • Pediatric: CrCl 30-60: 50mg/kg q24h; CrCl 11-29: 50mg/kg x1, then 25-50mg/kg q24h; CrCl <11: 50mg/kg x1, then 12.5-25mg/kg q24h; HD: 50mg/kg x1, then 25mg/kg q24h, give after dialysis; PD: 50mg/kg q48h
  • Hepatic Dosing
    • Adult: No adjustment
    • Pediatric: No adjustement

Contraindications

  • Allergy to class/drug (See also Cephalosporin Cross-reactivity
  • Caution if hypersensitive to PCN
  • Caution if recent antibiotic-associated colitis history
  • Caution if GI disorder history
  • caution if H. influenzae infection (pediatric patients)

Adverse Reactions

Serious

  • Anaphylaxis
  • Encephalopathy (patients with renal insufficiency more prone)
  • Seizures
  • Non-convulsive status epilepticus
  • Leukopenia
  • Thrombocytopenia
  • Agranulocytosis
  • Anemia, hemolytic
  • Aplastic anemia
  • Hemorrhage
  • Stevens-Johnson syndrome
  • Toxic epidermal necrolysis
  • Erythema multiforme
  • Clostridium difficile associated diarrhea

Common

Pharmacology

  • Half-life: 2 hours, 13.5 hours (HD), 19 hours (CAPD)
  • Metabolism: minimal, site unknown; CYP450: unknown
  • Excretion: urine primarily (85% unchanged)
  • Mechanism of Action: bactericidal; inhibits cell wall mucopeptide synthesis

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep S
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium X1
MSSA S
MRSA R
CA-MRSA R
Staph. Epidermidis I
C. jeikeium X1
L. monocytogenes R
Gram Negatives N. gonorrhoeae I
N. meningitidis S
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg S
Enterobacter sp, AmpC pos R
Serratia sp S
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. S
Citrobacter freundii S
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. I
Pseudomonas aeruginosa S
Burkholderia cepacia I
Stenotrophomonas maltophilia R
Yersinia enterocolitica S
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis R
Prevotella melaninogenica R
Clostridium difficile R
Clostridium (not difficile) X1
Fusobacterium necrophorum X1
Peptostreptococcus sp. S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  • Epocrates
  1. ↑ Sanford Guide to Antimicrobial Therapy 2014
  • Lexicomp

Accessed September 4, 2019

Obtenido de «https://www.wikem.org/w/index.php?title=Cefepime&oldid=386733»